LinusBio, a 2021 spinoff company from Mount Sinai, announced a Series A venture capital funding to deliver a novel platform that bridges genomics, the environment, and biological response. The company’s platform is based on new methods and technology developed by scientists at the Institute for Exposomic Research at Mount Sinai.
Autism prevalence has been rising steadily since the 1990s but despite extensive research, a genetic cause has not been identified. Experts from the Mount Sinai Institute for Exposomic Research explain how studying the environment can help prevent and better treat autism.
The third session of the 2022 Lunchtime Chats, featuring Manish Arora, BDS, MPH, PhD, Edith J. Baerwald Professor and Vice Chairman of the Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai
In a new book, Dr. Manish Arora and Dr. Paul Curtin of the Mount Sinai Institute for Exposomic Research suggest that a newly proposed component—the biodynamic interface—may better explain how humans interact with their environment
StrandDx™- ASD Exposome Sequencing Diagnostic was developed based on technology developed by researchers in the Institute for Exposomic Research at Mount Sinai.
Subject to regulatory approvals, the new company intends to launch its first product with StrandDx™- ASD a molecular biomarker for autism spectrum disorder that can be applied at birth, and can assist in early Autism Spectrum Disorder diagnosis.
Dr. Arora discuss how environmental factors in utero and early childhood may play a key role in the development of autism, ALS, and other complex neurological diseases.
Groundbreaking methodology of analyzing teeth discovers environmental exposures and helps identify early markers of disease
Mount Sinai Research Could Result in Early Diagnostic System for Autism Spectrum Disorder